Welcome to the first installment of the Pharmacy Pearls newsletter. This edition discusses the evidence behind some recently raised concerns surrounding PPI use along with guidance for tapering to minimize rebound hypersecretion. We hope you find this useful in your daily practice. Suggestions or comments may be directed to Jineane Venci, clinical pharmacist at jineane_venci@urmc.rochester.edu.
135 Corporate Woods, Suite 320
Rochester, New York 14623-1466
Phone: (585) 758-7823
Fax: (585) 424-1268
© Copyright - Accountable Health Partners - 2025
Website by: 
This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.
| ABI Value | Interpretation | Recommendation |
|---|---|---|
| Greater than 1.4 | Calcification/vessel hardening | Refer to vascular specialist |
| 1.0 - 1.4 | Normal | None |
| 0.9 - 1.0 | Acceptable | None |
| 0.8 - 0.9 | Some arterial disease | Treat risk factor |
| 0.5 - 0.8 | Moderate arterial disease | Refer to vascular specialist |
| Less than 0.5 | Severe arterial disease | Refer to vascular specialist |
